ReviewCurrent osteoporosis reports2023
Denosumab Discontinuation.
Review in Current osteoporosis reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Hypercalcemia after denosumab discontinuation in patients with osteoporosis: a systematic review and case report.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Pooled it
- Medication for bone loss in female patients with anorexia nervosa: a systematic review and management algorithm.Eating and weight disorders : EWD · 2025Pooled it
- Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review.Archives of endocrinology and metabolism · 2024Pooled it
- Bone density and remodeling after discontinuation of sequential therapy for premenopausal idiopathic osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Trial
- Bone Mineral Density Loss After Kidney Transplantation: Metabolic Determinants, Diagnostic Approaches, and Preventive Strategies.Kidney international reports · 2026Review
- Keeping bone resorption markers very low for 1 year after denosumab prevents bone loss at 2 years: the ReoLaus study.Archives of osteoporosis · 2026Article
- Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Atypical Femoral Fractures Induced by Anti-Resorptive Medications.Current osteoporosis reports · 2026Review
- Efficacy and safety of zoledronic acid versus denosumab in the treatment of primary osteoporosis: a single-center retrospective cohort study.Frontiers in endocrinology · 2026Article
- Denosumab Therapy in Dental Practice: Awareness, Risk Factors and Preventive Strategies.Journal of osteoporosis · 2026Review
- A Biocompatible Microdroplet Platform Incorporating MSC-Derived Exosomes for Bone Regeneration and Osteoporosis Treatment.International journal of nanomedicine · 2026Article
- Mechanisms and management strategies for exacerbated bone loss following denosumab discontinuation.Frontiers in aging · 2026Review
- [Diabetic Charcot neuroarthropathy initially misdiagnosed as rheumatoid arthritis and gout: A case report].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025Article
- Asian Federation of Osteoporosis Societies 2025 consensus on atypical femoral fractures in patients with osteoporosis.Osteoporosis and sarcopenia · 2025Review
- Two New Chromone Derivatives from a Marine Algicolous FungusMarine drugs · 2025Article
- Comparative outcomes of denosumab and zoledronic acid discontinuation in hip fracture surgery: a nationwide database study.Archives of osteoporosis · 2025Article
- Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets.Cancer medicine · 2025Review
- Beyond Bone Remodeling: Denosumab's Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases-A Narrative Review.Biomedicines · 2025Review
- Management of Adverse Skeletal Effects Following Bariatric Surgery Procedures in People Living with Obesity.Current osteoporosis reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation. RECENT
findingsTreatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bone turnover and a subsequent bone loss. During this phase of high bone turnover, an increased risk of fractures has been reported. Therefore, treatment with DMAB could be considered life-long. However, side-effects may prompt the need for discontinuation and moreover, treatment with DMAB may have increased BMD to levels where continuing treatment does not provide further fracture risk reduction. Patients stopping DMAB should be offered subsequent antiresorptive treatment with an intense monitoring regimen during the initial year as most of the bone loss occurs within these initial 12 months. In this review, we evaluated the literature published over the past 1 to 3 years investigating DMAB withdrawal with focus on bone turnover markers, bone mineral density, and fracture risk and the transition to other anti-osteoporosis therapies. Furthermore, we summarized the current recommendations of international guidelines. In this review, we evaluated the literature published over the past 1 to 3 years investigating denosumab (DMAB) discontinuation and the transition to other anti-osteoporosis therapies. Additionally, we summarized the current recommendations of international guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.